Stem Cell Therapy in China 2026: First Drug Approved, New Rules, and What Patients Need to Know
China’s first stem cell drug costs $2,750/dose vs $1.55M in the US (1/70th the price). New Decree 818 now regulates treatments. MSC therapies for knee OA from $4,900. Hainan Boao pilot zone welcomes international patients. Your complete safety guide.
Key Takeaways
- ✦In January 2025, China's National Medical Products Administration (NMPA) gave the green light to Aimmatoce Injection (睿铂生/艾米迈托赛注射液) — the country's first domestically developed stem cell drug.
- ✦818 (《生物医学新技术临床研究和临床转化应用管理条例》), signed in late 2024 or early 2025 and effective May 1, 2025, is China's first comprehensive regulation covering stem cells, gene editing, CAR-T, and tissue engineering.
- ✦TreatmentCost in ChinaStatusNotes Aimmatoce (MSC for aGVHD)$2,750/dose (¥19,800)Approved drug (NMPA)Available at major hospitals, full course ~$21,600 MSC for knee osteoarthritis~$4,900/session (¥36,000)Approved tech (Hainan Boao)For severe OA un...
- ✦If you're thinking about stem cell treatment in China, here's the safe path: 1.
China's stem cell therapy scene has changed dramatically in the past year. In 2025, the country approved its first homegrown stem cell drug and rolled out its first comprehensive regulation — Decree No. 818 — which took effect on May 1, 2025. This is a huge moment for international patients looking into stem cell treatment in China.
Let me break down what's shifted and what you need to know.
The Big News: China's First Stem Cell Drug
In January 2025, China's National Medical Products Administration (NMPA) gave the green light to Aimmatoce Injection (睿铂生/艾米迈托赛注射液) — the country's first domestically developed stem cell drug. It's an umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy for steroid-refractory acute graft-versus-host disease (aGVHD).
Pricing: ¥19,800 per dose (~$2,750 USD). A full course of 8 doses runs about ¥158,000 (~$21,600). (Sources: phirda.com, China Daily)
The New Rules: Decree 818
Decree No. 818 (《生物医学新技术临床研究和临床转化应用管理条例》), signed in late 2024 or early 2025 and effective May 1, 2025, is China's first comprehensive regulation covering stem cells, gene editing, CAR-T, and tissue engineering. Here's what matters for international patients:
Three Key Rules
What Treatments Are Available Now?
| Treatment | Cost in China | Status | Notes |
|---|---|---|---|
| Aimmatoce (MSC for aGVHD) | $2,750/dose (¥19,800) | Approved drug (NMPA) | Available at major hospitals, full course ~$21,600 |
| MSC for knee osteoarthritis | ~$4,900/session (¥36,000) | Approved tech (Hainan Boao) | For severe OA unresponsive to standard therapy |
| Autologous lung cell transplant | ~$20,500 (¥150,000) | Approved tech (Hainan Boao) | For lung fibrosis / chronic lung disease |
| MSC for ischemic heart disease | ~$8,200 (¥60,000) | Approved tech (Hainan Boao) | For significant left ventricular dysfunction |
| Clinical trials (various indications) | Free (by law) | Phase I-III trials | IND applications approved; must be at Grade 3A hospital |
Sources: China NMPA, Hainan Boao Lecheng Pilot Zone, published fee schedules (2025-2026). Prices subject to change.
How to Access Stem Cell Therapy Safely in China
If you're thinking about stem cell treatment in China, here's the safe path:
1. Target the right pathway: Only go for treatments that are either an NMPA-approved drug or an NHC-approved medical technology at a regulated hospital.
2. Go to a Grade 3A hospital: Only China's top-tier hospitals are legally allowed to provide stem cell treatments. Think Peking University People's Hospital, Beijing Jishuitan Hospital, Tongji Hospital (Wuhan), and the hospitals in the Hainan Boao Lecheng Medical Zone.
3. Consider the Hainan Boao Pilot Zone: This is China's designated medical tourism zone, with easier access for international patients and approved stem cell therapies available.
4. Verify the pricing upfront: Legitimate treatments have a clear fee schedule. Ask for a written cost estimate.
5. Be super cautious about unlicensed clinics: Multiple clinics have been shut down in 2025-2026 for illegal stem cell practices, including cases in Wuhan, Hainan, Shanghai, and Tianjin with fines up to $275,000 (¥2 million).
What's Coming: Pipeline Outlook
As of December 2025, China had over 200 stem cell drug IND applications submitted, with many approved for clinical trials. Shanghai and Beijing lead in IND applications. The dominant cell type: mesenchymal stem cells (73.6% of INDs). Key indications in Phase III include knee osteoarthritis, liver failure, refractory anal fistula, and heart failure. Expect multiple approvals through 2026-2027. (Source: BIOCHINA2026)
Important Warning for International Patients
Under Decree 818, which took effect May 1, 2025, legitimate clinical research cannot charge patients any fees. That means any clinic offering "stem cell research participation" for a fee is operating illegally. Enforcement has been aggressive — several clinics have already been fined and shut down in 2025-2026. If you're paying for stem cell treatment in China, make sure it's for an approved clinical application, not a research study.
The Bottom Line
China has gone from a poorly regulated market to a structured, affordable destination for stem cell therapy. With the first approved drug priced competitively, a growing pipeline of treatments entering Phase III, and a clear regulatory framework under Decree 818, China offers genuine options for patients who need stem cell treatments they can't afford at home. The key is using regulated channels — Grade 3A hospitals or the Hainan Boao pilot zone — and steering clear of unlicensed operators.
Hi, I'm Peng — Your China Travel Insider
I've been helping travelers explore China for 15 years. Every inquiry I receive gets a personal reply from me — no chatbots, no automated responses.
Ready to plan your China trip?
Every trip is different. Tell me what you're looking for and I'll build a custom itinerary that fits your style, budget, and schedule.